OnCo
peoplePerson

Jean-Charles Soria

Ran the phase 1 unit that pioneered many targeted therapies, and led the FLAURA trial that made osimertinib first-line.

Jean-Charles Soria built Gustave Roussy's DITEP early-phase unit, led FLAURA (osimertinib first-line), and later served as Director General and as an industry R&D leader before returning to academic medicine.

Role
Professor of Medicine, Paris-Saclay; former Director General, Gustave Roussy
Institution
Gustave Roussy
Specialisms
Early drug developmentEGFR-mutant lung cancerPhase 1 trials
Profiles

Papers

1top
TitleJournalYear
Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer (FLAURA)NEJM2018

Key papers

1top
rctNew England Journal of Medicine 2018changed practice
FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer

Anyone diagnosed with advanced lung cancer should have EGFR testing before treatment, because osimertinib as the first drug gives the longest disease control, protects the brain, and is well tolerated. Chemotherapy is not the first step for these patients. The remaining questions are whether to intensify upfront (adding chemotherapy or amivantamab) and how to treat resistance when it develops.

Connected

5top

cancers

1
Non-small-cell lung cancer

targets

1
EGFR

drugs

1
ApprovedSmall-molecule kinase inhibitor (EGFR)
Osimertinib · Tagrisso

institutions

1
Gustave Roussy

key papers

1
FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer